Top 5 Companies Developing Allogeneic Cell Therapies

Published: October 2023

Allogeneic cell therapies represent a promising and rapidly advancing paradigm of the healthcare industry, with the potential to revolutionize the regenerative medicines industry We analyzed more than 190 allogeneic cell therapy developers. In this article, discover the top 5 companies engaged in developing allogeneic cell therapies.

Cell therapy refers to the introduction of engineered cells into a patient's body to treat, replace or repair damaged / dysfunctional tissues. The cell therapies can either be derived from the patient’s own body (autologous therapy) or from a healthy donor (allogeneic therapy). Specifically, in case of allogeneic cell therapy, the cells are collected from a suitable donor’s bone marrow, peripheral blood, placenta or cord blood. The selected cells can be directly given to the patient or engineered in order to elicit a suitable therapeutic response. Once the optimal phenotype is achieved, the selected cells undergo in-vitro amplification. The final cells are cryopreserved to ensure long-term viability and availability for future use. 

Some of the advantages of allogeneic cell therapy includes easy availability, enhanced product quality, less product variability, potential to treat all the eligible patients, scalable manufacturing process, reduced processing time and cost-effectiveness. Further, the different types of allogeneic cell therapies include Chimeric Antigen Receptor (CAR T Cell Therapy), Dendritic cell therapies, T-cell Receptor (TCR Therapy) therapies, Tumor Infiltrating Lymphocyte (TIL Therapy), Natural Killer (NK) cell therapies, Novel T-cell therapy and Stem cell therapy. 

Some examples of recently approved allogeneic cell therapies include:

  • Ebvallo™ (developed by Atara Biotherapeutics) - Allogeneic T-cell immunotherapy used to treat relapsed/refractory Epstein?Barr virus positive post?transplant lymphoproliferative disease
  • Omisirge (developed by Gamida Cell) - Nicotinamide modified allogeneic hematopoietic progenitor cell therapy used to treat hematologic malignancies
  • Stempeucel® (developed by Stempeutics Research) - Allogeneic mesenchymal stem cells (MSC) derived therapy used to treat knee osteoarthritis

Driven by the rising prevalence of chronic diseases, rapid progress in clinical development initiatives and the introduction of new reforms in legislation pertaining to cell therapies, the field has gained significant traction in the last few years.

Roots Analysis has conducted an exhaustive study on Allogeneic Cell Therapy Market, featuring the current market landscape and future opportunities for companies developing allogenic cell therapies over a span of 12 years.

Table of Contents

Below, we have listed (in decreasing order of the number of allogeneic cell therapies developed), the top 5 allogenic cell therapy developers:
1. Fate Therapeutics
2. Allogene Therapeutics
3. Artiva Biotherapeutics
4. CHABiotech
5. Cellenkos

Interested in exploring all 190+ allogeneic cell therapies developers across various regions?

Fate Therapeutics Uses Induced Pluripotent Stem Cells as a Renewable Source for Mass Production of Cellular Treatments; Pipeline Re-evaluated in 2022

Fate Therapeutics - Allogeneic Cell Therapies

Fate Therapeutics is a clinical-stage biopharmaceutical firm, focusing on the development of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to treat autoimmune and oncological disorders. As per the company website, the company’s iPSC platform is supported by an intellectual property portfolio of more than 400 issued patents and 450 pending patent applications. Further, it is currently evaluating various allogeneic NK cell therapy as monotherapy or in combination with other anti-cancer agents (such as monoclonal antibodies).

The following table presents the details of the allogeneic cell therapies under development by Fate Therapeutics.

S. No     Therapy Name              Phase of Development        Therapeutic Area                                 
FT576 Phase I Multiple Myeloma
2 FT819 Phase I B-cell Malignancies
3 FT522 Preclinical B-cell Lymphoma
4 FT825 Preclinical Solid Tumors
5 FT522 Preclinical Undisclosed Autoimmune Disorder

The company soon plans to initiate phase I trial in B-cell lymphoma patients evaluating FT522, a CAR NK targeting CD19. Additionally, IND submission for FT825, HER 2 targeted CAR T being co-developed with Ono Pharmaceutical, is planned for 2023.

Recent Developments: 

  • In January 2023, Fate Therapeutics discontinued the development of multiple programs including FT516, FT538, FT536 and FT596, citing expense reduction and pipeline prioritization.1 
  • In December 2022, the company participated in the 64th American Society of Hematology (ASH) Annual Meeting and Exposition to present the different innovative approaches to administer allogeneic cell-based oncological therapies, without the requirement of conditioning chemotherapy.
  • In June 2022, the company expanded its collaboration with ONO Pharmaceutical to develop allogeneic, CAR-NK cell therapy candidates to treat solid tumors.

Further information related to the company’s allogeneic cell therapies is available in the full report.

Using its Proprietary AlloCAR T™ Platform, The Company Aims to Offer Safe and Efficacious off-the-shelf Cell Therapies 

Allogene Therapeutics - Allogeneic Cell Therapies

Allogene Therapeutics specializes in the development of off-the-shelf CAR-T cell therapies in order to treat blood cancers and solid tumors. Through its 136,000 square-foot facility located in California, US, the company offers clinical and commercial manufacturing, analytical testing and distribution of cell products.

The following table presents the details of the allogeneic cell therapies under development by Allogene Therapeutics.

S. No     Therapy Name                       Phase of Development        Therapeutic Area                                 
ALLO-501A Phase II B-Cell Lymphoma (3rd Line)
2 ALLO-605 Phase I / II Multiple Myeloma
3 ALLO-501A + ALLO-647 Phase I / II B-Cell Lymphoma
4 ALLO-715 Phase I Multiple Myeloma
5 ALLO-316 Phase I Renal Cell Carcinoma
6 ALLO-182 Preclinical Gastric Cancer, Pancreatic Cancer
7 ALLO-213 Preclinical Small Cell Lung Cancer
8 ALLO-316 Preclinical Unspecified Hematological Malignancy
9 ALLO-316 Preclinical Unspecified Solid Tumor
10 ALLO-501A Preclinical B-Cell Lymphoma
11 ALLO-819 Preclinical Acute Myeloid Leukemia

Recent Developments: 

  • In September 2023, the company participated in Society for Immunotherapy of Cancer (SITC) Annual Meeting, held in California, US to showcase its next generation AlloCAR T™ platform and product candidates.
  • In February 2023, the company participated in Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Alberta, Canada, to present preclinical data for the company’s next generation Dagger™ platform technology.
  • FDA granted RMAT designation (in June 2022) to its allogeneic CAR T therapy targeting CD19, namely ALLO-501A.
  • FDA granted Orphan Drug Designation (in April 2022) and Fast Track Designation (in July 2021) to its allogeneic CAR T therapy targeting BCMA, namely ALLO-605.
  • FDA granted Fast Track Designation (in March 2022) to its allogeneic CAR T therapy targeting CD70, namely ALLO-316.
  • FDA granted Orphan Drug Designation (in August 2021) and RMAT Designation (in April 2021) to its allogeneic CAR T therapy targeting BCMA, namely ALLO-715.

Further information related to the company’s allogeneic cell therapies is available in the full report.

Artiva Biotherapeutics has Collaborated with Several Leading Pharmaceutical Companies to Progress the Clinical Application of Allogeneic NK Cell Therapy

Artiva Biotherapeutics - Allogeneic Cell Therapies

Artiva Biotherapeutics focuses on the development of allogeneic NK cell therapies and CAR-NK cell therapies, from umbilical cord blood of healthy donors. The company’s non-genetically modified NK cells are useful in enhancing antibody-dependent cellular cytotoxicity (ADCC) in patients undergoing monoclonal antibody therapy. Further, its genetically modified CAR-NK cell therapies couple the efficacy of CARs with the safety features of NK cells. It is worth mentioning that the firm has established exclusive partnerships with GC Cell and Merck to evaluate novel NK cell therapies in clinical trials.
The following table presents the details of the allogeneic cell therapies under development by Artiva Biotherapeutics.

S. No     Therapy Name              Phase of Development        Therapeutic Area                                 
AB-101 Phase I / II Non-Hodgkin's Lymphoma
2 AB-101 + AFM-13 Phase II Hodgkin's Lymphoma and CD30+ PTCL  
3 AB-101 + Rituximab Preclinical Lupus Nephritis
4 AB-201 Preclinical Breast Cancer, Gastric Cancer
5 AB-205 / CD5 CAR-NK    Preclinical T-Cell Lymphoma
6 AB-MK-001 Preclinical Unspecified Solid Tumor
7 AB-MK-002 Preclinical Unspecified Solid Tumor

The company soon plans to initiate phase I trial of AB-101 in Systemic Lupus Erythematosus in patients with active lupus nephritis, IND clearance for which was received in August 2023.2

Recent Developments: 

  • In January 2023, FDA granted Fast Track Designation to cord blood-derived, allogeneic, NK cell therapy, namely AB-101 (for the treatment of relapsed/refractory non-Hodgkin lymphoma).
  • In November 2022, the company entered into a partnership with Affimed to evaluate the combination of its allogeneic cell therapy, AB-101 with the latter company’s Innate Cell Engager (ICE®) AFM13.
  • In June 2022, the company opened a research and development laboratory in San Diego, California to support NK and CAR-NK cell production.
  • In April 2022, Artiva Biotherapeutics entered into a partnership with Merck to evaluate the combination of NK cells (generated from Artiva’s AlloNK™ platform) with tri-specific NK-cell engagers.

Further information related to the company’s allogeneic cell therapies is available in the full report.

Owing to its State-of-the-Art Facilities and Technical Expertise, CHABiotech Contributes to the Regenerative Medicine Industry

CHABiotech - Allogeneic Cell Therapies

CHABiotech is a biotechnology company engaged in the development of cell and gene therapies (derived from embryonic stem cells, adult stem cells and immune cells) for the treatment of aging-related diseases, cancer and incurable diseases. The company states to have registered around 90 patents for cell technologies. In addition, the firm offers (safe and reliable) cord blood banking service as well as conducts research on cord blood-based therapies. 

The following table presents the details of the allogeneic cell therapies under development by CHABiotech.

S. No     Therapy Name                                             Phase of Development        Therapeutic Area                                 
CordSTEM-ST Phase II Stroke
2 MA09-hRPE / hESC-RPE Phase II Age-Related Macular Degeneration
3 CordSTEM-DD Phase I / II Degenerative Disc Disease
4 CordSTEM-DD Phase I Degenerative Disc Disease
5 MA09-hRPE / hESC-RPE / ASP7316 Phase I Stargardt Disease
6 CordSTEM-POI Phase I Ovarian Insufficiency
7 Allo-NK Preclinical Unspecified Cancer
8 FMD-NPC Preclinical Parkinson's Disease

Recent Developments: 

  • In March 2023, the company entered into a technology transfer agreement with Astellas Institute for Regenerative Medicine (AIRM) for its retinal pigment epithelial cells (RPE) and embryonic cells (blastomere) technologies.

The company aims to develop novel treatments by conducting basic research and clinical studies up to commercialization stage. In 2021, CHA Biolab received permission to develop advanced biopharmaceutical products, and approval of cell processing facility.

Further information related to the company’s allogeneic cell therapies is available in the full report.

Leveraging its Cord Blood T-Regulatory Cells; Activated And Enriched (CRANE™) Platform, Cellenkos aims to advance research in the clinical domain

Cellenkos - Allogeneic Cell Therapies

Cellenkosis is a patient-centric, allogeneic T-regulatory cell (Treg therapy) therapy developer. The Tregs developed by the company are suppressor cells that treat inflammation through various direct as well as indirect interactions; some of their advantages include low immunogenicity, surplus availability and large-scale expansion. Further, its GMP manufacturing facility (established in 2017) is located in Texas, US and has expertise in technology transfer, process development and scale up.

The following table presents the details of the allogeneic cell therapies under development by Cellenkos.

S. No     Therapy Name              Phase of Development        Therapeutic Area                                 
CK0801 Phase I Bone Marrow Failure Syndrome
2 CK0802 Phase I Acute Respiratory Distress Syndrome
3 CK0803 Phase I Amyotrophic Lateral Sclerosis
4 CK0804 Phase I Myelofibrosis
5 CK0805 Preclinical Graft versus Host Disease
6 CK0806 Preclinical iPEX Syndrome
7 CK0807 Preclinical T-Cell Lymphoma
8 CK0808 Preclinical Lupus Nephritis
9 CK0803 Preclinical Parkinson’s Disease

Recent Developments: Leveraging its umbilical cord blood proprietary platform, Cellenkos strives to develop Tregs to treat autoimmune and inflammatory disorders. In September 2022, the company received clearance from the FDA to conduct Phase 1 clinical trial followed by a Phase 1b randomized, double blind, placebo control study of CK0803. Further, in November 2021, the company secured USD 15 Million through Series A financing to accelerate the development of its Treg therapies.

  • In May 2023, the company dosed first patient in its phase I clinical trial for CK0803, an allogeneic Treg therapy for treatment of Amyotrophic Lateral Sclerosis.3
  • In January 2023, the first patient was dosed with CK0804 in phase I clinical trial for treatment of myelofibrosis.

Further information related to the company’s allogeneic cell therapies is available in the full report. 

What About the Other Allogeneic Cell Therapies Developers?

The above presentation features the top 10 allogeneic cell therapies developers selected from a pool of over 190 firms that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at

About Author

Simran Kaur

Simran, a Senior Business Analysis, has been an integral part of the Roots Analysis team since 2020. Holding a Master’s and Bachelor’s in pharmacy from a prestigious institution, she embarked on her professional journey with a strong academic foundation and an interest in life sciences domain. Her keenness to learn more about the emerging trends, regulatory dynamics and technological advancements enables her to provide comprehensive analyses. Till date, she has diligently contributed to over 15 comprehensive research reports on trending topics, ranging from anti-aging therapeutics, allogeneic cell therapies, lipid nanoparticles, pre-sterilized pharmaceutical packaging to next generation sequencing kits.



  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry